Hagelberg R S, Jolly P C, Anderson R P
Am J Surg. 1984 Jul;148(1):125-31. doi: 10.1016/0002-9610(84)90299-x.
Twenty-eight patients with inflammatory carcinoma of the breast have been retrospectively reviewed. Overall 5 year survival was 25 percent. There was a trend toward improved survival in patients who received chemotherapy which did not achieve statistical significance. Sixteen patients underwent mastectomy as part of their treatment. These patients had a 48 percent 5 year survival which was significantly better than the survival in patients who did not undergo mastectomy. Furthermore, mastectomy resulted in better control of the local disease. Of 12 patients who did not undergo mastectomy, local control was initially obtained in only 2, and both of these patients suffered local recurrence within 1 year. Our data support the conclusion that mastectomy be combined with preoperative and postoperative multiagent cytotoxic chemotherapy in the treatment of inflammatory carcinoma of the breast. More precise staging may permit better prognostic stratification of patients with this highly malignant cancer.
对28例炎性乳腺癌患者进行了回顾性研究。总体5年生存率为25%。接受化疗的患者有生存改善的趋势,但未达到统计学意义。16例患者接受了乳房切除术作为其治疗的一部分。这些患者的5年生存率为48%,明显优于未接受乳房切除术的患者。此外,乳房切除术能更好地控制局部疾病。在12例未接受乳房切除术的患者中,仅2例最初获得了局部控制,且这2例患者均在1年内出现局部复发。我们的数据支持这样的结论,即乳房切除术应与术前和术后多药细胞毒性化疗联合用于炎性乳腺癌的治疗。更精确的分期可能使这种高度恶性肿瘤患者的预后分层更好。